You are here

News

November

Correlation between public and family cord blood banks per country in 2015
Nov 2016   Slides from Parent's Guide to Cord Blood Foundation at Phacilitate Cord Blood and Tissue Webinar 16 Nov. 2016. All presentations will be archived.
Babycell cord blood transplant patient Neha with her donor brother
Nov 2016   Neha is now a healthy six year old after a cord blood transplant from her brother thanks to the family cord blood bank Babycell in India.
AmnioChor
Nov 2016   We see rapid growth in AMP-based injectable products being offered in the U.S., and targeted specifically for allogeneic use. Does this meet FDA guidance?

October

Parent's Guide to Cord Blood Foundation logo
Oct 2016   Commerical banks are NOT the dominant source of 2015 funding for Parent's Guide to Cord Blood Foundation.
Phacilitate 2017 Cell & Gene Therapy World
Oct 2016   The newly launched Phacilitate Cord Blood will be part of Phacilitate Cell & Gene Therapy World in Miami January 2017.
AmnioChor
Oct 2016   AmnioChor proposes that amniotic membrane of the placenta (AMP) is a paradigm shifter because a single placenta provides multiple doses for now or later, that can be tissue or cellular therapy, can be autologous, matched allogeneic, or allogeneic therapy.

September

AABB Center for Cellular Therapies
Sep 2016   The AABB Center for Cellular Therapies is launching a new membership benefit for Spanish-speaking individuals who are interested in cellular therapies, including cord blood banking.
Zayed thalassemia patient with brother and stem cell donor Mohammed
Sep 2016   Zayed’s transplant from his brother Mohammed marks the first release of privately stored cord blood stem cells from the UAE to the US.
AmnioChor
Sep 2016   AmnioChor has compiled a spreadsheet (available for download) of all tissue products that are currently manufactured from the Amniotic Membrane of the Placenta (AMP).

August

Institute of Cell Therapy Pancreonecrosis Histology
Aug 2016   The Ministry of Health of Ukraine has approved a cell therapy for pancreonecrosis, a condition with high mortality, that was developed by scientists at the Institute of Cell Therapy. This novel therapy combines the traditional management of pancreonecrosis with infusions of stem cells from cord blood, plus the use of native cord tissue in the surgical intervention for wound drainage and repair.